Literature DB >> 8827049

Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma.

M V Kato1, T Shimizu, K Ishizaki, A Kaneko, D W Yandell, J Toguchida, M S Sasaki.   

Abstract

Loss of heterozygosity (LOH) on chromosome 17 and mutations of the p53 gene were examined in 25 retinoblastomas (RB), consisting of three familial tumors, nine hereditary tumors without family history, 11 non-hereditary tumors, one recurrent tumor and one lung-metastatic tumor. LOH on chromosome 17 was detected in only one of the 23 primary RB. No mutations of the p53 gene were detected in the primary tumors. A recurrent tumor showed LOH on the short arm region of chromosome 17. LOH on chromosome 17 and a point mutation of the p53 gene were also detected in a metastatic tumor. These results suggest that LOH on chromosome 17 and mutation of the p53 gene may not be associated with the development of primary RB, but may play a role in the progression of RB.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827049     DOI: 10.1016/0304-3835(96)04305-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

1.  Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability.

Authors:  Vassiliki Poulaki; Constantine S Mitsiades; Antonia M Joussen; Alexandra Lappas; Bernd Kirchhof; Nicholas Mitsiades
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA.

Authors:  Gabriella Livide; Maria Carmela Epistolato; Mariangela Amenduni; Vittoria Disciglio; Annabella Marozza; Maria Antonietta Mencarelli; Paolo Toti; Stefano Lazzi; Theodora Hadjistilianou; Sonia De Francesco; Alfonso D'Ambrosio; Alessandra Renieri; Francesca Ariani
Journal:  Pathol Oncol Res       Date:  2012-01-26       Impact factor: 3.201

3.  Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis.

Authors:  R Nabbout; M Santos; Y Rolland; O Delalande; O Dulac; C Chiron
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-03       Impact factor: 10.154

4.  MDM2/MDMX: Master negative regulators for p53 and RB.

Authors:  Linshan Hu; Haibo Zhang; Johann Bergholz; Shengnan Sun; Zhi-Xiong Jim Xiao
Journal:  Mol Cell Oncol       Date:  2016-02-18

Review 5.  The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Authors:  Christine M Eischen; Guillermina Lozano
Journal:  Hum Mutat       Date:  2014-03-06       Impact factor: 4.878

6.  Childhood cancer and developmental biology a crucial partnership.

Authors:  Sara Federico; Rachel Brennan; Michael A Dyer
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

7.  MDMX exerts its oncogenic activity via suppression of retinoblastoma protein.

Authors:  H Zhang; L Hu; W Qiu; T Deng; Y Zhang; J Bergholz; Z-X Xiao
Journal:  Oncogene       Date:  2015-02-23       Impact factor: 9.867

Review 8.  The genomic landscape of retinoblastoma: a review.

Authors:  Brigitte L Thériault; Helen Dimaras; Brenda L Gallie; Timothy W Corson
Journal:  Clin Exp Ophthalmol       Date:  2013-05-22       Impact factor: 4.207

9.  The components of Drosophila histone chaperone dCAF-1 are required for the cell death phenotype associated with rbf1 mutation.

Authors:  Heather Collins; Nam-Sung Moon
Journal:  G3 (Bethesda)       Date:  2013-10-03       Impact factor: 3.154

10.  Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma.

Authors:  Ying Guo; Sanja Pajovic; Brenda L Gallie
Journal:  Biochem Biophys Res Commun       Date:  2008-07-21       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.